Clobenate0.05%

Clobenate 0.05% is a super-high-potency (Group I) topical corticosteroid. Its use is classified by strength of evidence as follows:

Established / Approved Uses

• Short-term (up to 2 consecutive weeks) treatment of moderate-to-severe inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults and adolescents, such as psoriasis (localized plaques, excluding widespread plaque-type disease) and eczema/atopic dermatitis, that have not responded adequately to less potent topical corticosteroids.
• Lichen planus and discoid lupus erythematosus affecting the skin, when a very potent corticosteroid is clinically indicated.

Guideline-Supported / Specialist Uses

• Localized alopecia areata (patchy hair loss), used under dermatologist supervision as part of a broader treatment plan.
• Severe chronic hand or foot eczema recalcitrant to standard-potency corticosteroids, under specialist supervision.
• Vulvar lichen sclerosus, used as a specific short-course, physician-supervised regimen in gynecology/dermatology practice despite the general caution against use in the groin region for other indications.

Off-Label Uses

• Adjunctive use in vitiligo (localized patches), sometimes combined with other therapies.
• Palmoplantar pustulosis and other localized pustular or lichenified dermatoses resistant to weaker agents.

Clobenate 0.05% is reserved for short courses on limited body-surface areas and is not intended for long-term or first-line use in mild skin conditions.

Clobenate 0.05% is available as a topical preparation (cream, ointment, lotion, gel, solution, or scalp application, depending on brand) containing Clobetasol Propionate as the active ingredient, typically at a strength of 0.05% w/w (0.5 mg per gram or per mL) in a pharmaceutically suitable base appropriate to the formulation and body site being treated.

Clobenate 0.05% is a synthetic, halogenated corticosteroid belonging to the super-high-potency (Group I/Class I) category of topical steroids — among the most potent topical corticosteroids available. It is formulated for cutaneous (skin) application only and is used to relieve inflammation, redness, swelling, and itching associated with a range of steroid-responsive dermatological conditions that have failed to respond to weaker corticosteroids.

Because of its high potency, Clobenate 0.05% is intended for short, well-defined courses of treatment on limited areas of the body, under medical supervision, rather than for routine or prolonged use.

Clobenate 0.05% works by binding to intracellular glucocorticoid receptors in skin cells, forming a complex that translocates to the nucleus and modulates gene transcription. This produces:

• Anti-inflammatory effects — inhibition of phospholipase A2 reduces release of arachidonic acid, thereby decreasing production of prostaglandins and leukotrienes.
• Immunosuppressive/antiproliferative effects — reduced migration of inflammatory cells (neutrophils, macrophages) and reduced keratinocyte proliferation, useful in hyperproliferative conditions such as psoriasis.
• Vasoconstrictive and antipruritic effects — reduces local blood flow and itching in affected skin.

Topical application generally limits systemic absorption, but because Clobenate 0.05% is extremely potent, clinically significant systemic absorption can occur with extensive application, prolonged use, use on thin or damaged skin, or use under occlusion, which can suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Clobenate 0.05% is for external (topical/cutaneous) use only and must not be swallowed, or applied to the eyes, mouth, or mucous membranes.

• Wash and dry hands before application (unless the hands are the area being treated).
• Apply a thin layer to the affected skin only and rub in gently until the medicine disappears.
• Wash hands thoroughly after application, unless the hands are the treated area.
• Do not cover the treated area with airtight/occlusive dressings, bandages, or plastic wrap unless a physician specifically instructs otherwise, as this markedly increases absorption.
• Avoid contact with the eyes; if accidental contact occurs, rinse thoroughly with water.
• Do not use more often, in a larger amount, or for longer than prescribed.

Clobenate 0.05% has a low potential for clinically significant drug interactions when used topically on limited areas for short durations, since systemic absorption is normally minimal. However, the following are recognized as clinically relevant when significant systemic absorption occurs (e.g., with extensive application, prolonged use, or use under occlusion):

• Other corticosteroids (topical, inhaled, or systemic): concurrent use increases the cumulative corticosteroid burden and the risk of HPA-axis suppression and Cushingoid effects.
• Strong CYP3A4 inhibitors (e.g., ritonavir, itraconazole, ketoconazole): may increase systemic corticosteroid exposure if substantial absorption occurs, increasing the risk of systemic side effects.
• Live or live-attenuated vaccines: significant systemic corticosteroid exposure can reduce immune response to vaccines; avoid extensive/prolonged use around the time of vaccination unless advised by a physician.

Always inform your physician or pharmacist about all other medicines, including other topical products, being used with Clobenate 0.05%.

Most side effects of Clobenate 0.05% are local and occur at the application site. Systemic side effects are uncommon with short-term, limited-area use but become more likely with prolonged or extensive application.

Common (local)

• Burning or stinging sensation
• Itching, dryness, or irritation of the skin
• Redness (erythema)

Less Common (local, with prolonged or extensive use)

• Skin atrophy (thinning), striae (stretch marks), telangiectasia (visible small blood vessels)
• Folliculitis, acneiform eruptions, hypertrichosis (excess hair growth)
• Hypopigmentation or hyperpigmentation of treated skin
• Allergic contact dermatitis, secondary skin infection

Rare/Systemic (with extensive, prolonged, or occlusive use)

• Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingoid features, hyperglycemia (see Precautions and Warnings)

Patients should contact their physician if any persistent, worsening, or unusual reaction occurs.

Pregnancy: There are no adequate, well-controlled studies of Clobenate 0.05% in pregnant women, and high-potency topical corticosteroids have shown adverse effects on the fetus in animal studies at high systemic exposures. Clobenate 0.05% should be used during pregnancy only if clearly needed, at the smallest effective amount and for the shortest duration, and only if the potential benefit justifies the potential risk to the fetus. A physician should always be consulted before use in pregnancy.

Lactation: It is not known whether topical use of Clobenate 0.05% results in sufficient systemic absorption to appear in breast milk in clinically significant amounts. As a precaution, breastfeeding mothers should avoid applying Clobenate 0.05% directly to the breast/nipple area and should consult a physician before use, using it only if clearly needed and for the shortest necessary duration.

Clobenate 0.05% is one of the most potent topical corticosteroids available and requires strict adherence to the following precautions:

• HPA-axis suppression: Systemic absorption can occur even with recommended use, and is more likely with extensive body-surface-area treatment, prolonged use, or use under occlusion, potentially causing reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, or unmasking of latent diabetes. Duration should be limited (generally no more than 2 consecutive weeks, up to 4 weeks for psoriasis under supervision) and total weekly quantity should not exceed 50 g.
• Skin atrophy and related changes: Prolonged or extensive use can cause skin thinning, striae, and telangiectasia, particularly on the face and skin folds; some changes may be irreversible.
• Restricted-use areas: Avoid application to the face, groin, axillae, or other skin folds, and avoid use under occlusive dressings, unless specifically directed by a physician, due to increased absorption and atrophy risk in these areas.
• Tachyphylaxis: Reduced response may occur with continuous prolonged use; intermittent treatment or a brief drug-free period may be recommended by the physician.
• Local irritation and infection: Discontinue if irritation or allergic contact dermatitis develops. If a skin infection is present or develops during treatment, appropriate antimicrobial therapy should be started; discontinue Clobenate 0.05% if the infection does not respond promptly.
• Eye exposure: Avoid contact with the eyes; prolonged periocular use may increase the risk of glaucoma or cataracts.
• Pediatric caution: Children are at greater risk of HPA-axis suppression and Cushingoid effects due to a larger skin-surface-to-body-mass ratio; use only under close medical supervision.
• Not for widespread or long-term use: Clobenate 0.05% is not intended as a first-line or maintenance therapy for common, mild skin conditions.

Excessive or prolonged use of Clobenate 0.05%, especially over large areas of the body or under occlusion, can lead to significant systemic absorption of the corticosteroid, resulting in effects such as HPA-axis suppression, Cushingoid features (rounded face, weight gain, thinning skin), high blood sugar, or, in children, growth suppression.

If accidental ingestion occurs, or if signs of systemic corticosteroid excess (such as unusual weight gain, marked mood changes, high blood sugar, or severe skin thinning) develop, seek immediate medical attention or contact a poison control center. Do not attempt to self-treat a suspected overdose; management should be guided by a physician and generally involves discontinuing the drug and gradual tapering when the drug has been used long-term, along with monitoring and supportive care as advised by a doctor.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the container tightly closed and out of reach of children.

Pediatric patients: Clobenate 0.05% is generally not recommended for children under 12 years of age (some formulations restrict use under 1 year); when a physician determines it is necessary in a child, it should be used at the lowest effective amount for the shortest possible duration due to a heightened risk of HPA-axis suppression and Cushingoid effects (see Pediatric Use).

Elderly patients: Limited specific data exist in elderly patients; general dosing recommendations apply, with attention to thinner, more fragile skin, which may increase local absorption and risk of skin atrophy.

Hepatic/renal impairment: No specific dose adjustment has been established for topical use, as systemic exposure is normally low; however, caution is advised with extensive application, since impaired hepatic or renal function could theoretically reduce clearance of any absorbed drug.

Pregnancy and lactation: See Pregnancy and Lactation section for detailed guidance.

Treatment with Clobenate 0.05% should generally be limited to a maximum of 2 consecutive weeks for most corticosteroid-responsive dermatoses, and up to 4 consecutive weeks for localized plaque psoriasis under close physician supervision. The total amount used should not exceed 50 g per week. If there is no improvement within 2 weeks, treatment should be reassessed by a physician. Clobenate 0.05% is not intended for continuous, long-term use; repeated or extended courses should only occur under medical supervision, with periodic reassessment of the need for continued therapy.

Topical Corticosteroid (Super-High Potency / Group I)

Clobenate 0.05% exerts its effect by diffusing across cell membranes and binding to glucocorticoid receptors in the cytoplasm of skin cells. The activated receptor-drug complex enters the nucleus and alters the transcription of genes involved in inflammation, resulting in:

• Reduced synthesis and release of inflammatory mediators (prostaglandins, leukotrienes, cytokines) via inhibition of phospholipase A2.
• Suppression of inflammatory cell migration and activity (neutrophils, macrophages, lymphocytes) in the skin.
• Inhibition of keratinocyte and fibroblast proliferation, reducing the scaling and thickening seen in conditions like psoriasis.
• Local vasoconstriction, contributing to reduced redness and swelling.

The net effect is a marked reduction in cutaneous inflammation, itching, and abnormal cell proliferation at the site of application.

C

The safety and efficacy of Clobenate 0.05% in children have not been as thoroughly established as in adults, and most labeling restricts routine use to patients 12 years of age and older (with some specific formulations restricted further, e.g., not for use under 1 year of age, and scalp/shampoo forms generally not recommended under 18 years).

Children, because of a larger skin-surface-area-to-body-weight ratio, absorb proportionally more topical corticosteroid and are therefore at greater risk of HPA-axis suppression, Cushing's syndrome, and, with prolonged use, growth retardation and delayed weight gain, as well as intracranial hypertension (reported rarely with potent topical corticosteroids in children).

When a physician determines that use in a child is necessary, treatment should be limited to the smallest effective area and the shortest possible duration (often around 5 days), with close medical supervision and monitoring for signs of systemic absorption.